TY - JOUR T1 - A Novel and Orally Active Poly(ADP-Ribose) Polymerase Inhibitor, KR-33889 [2-[Methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1<em>H</em>-benzimidazole-4-carboxylic Acid Amide], Attenuates Injury in in Vitro Model of Cell Death and in Vivo Model of Cardiac Ischemia JF - Journal of Pharmacology and Experimental Therapeutics JO - J Pharmacol Exp Ther SP - 10 LP - 18 DO - 10.1124/jpet.108.143719 VL - 328 IS - 1 AU - Kwang-Seok Oh AU - Sunkyung Lee AU - Kyu Yang Yi AU - Ho Won Seo AU - Hyun-Na Koo AU - Byung Ho Lee Y1 - 2009/01/01 UR - http://jpet.aspetjournals.org/content/328/1/10.abstract N2 - Blocking of poly(ADP-ribose) polymerase (PARP)-1 has been expected to protect the heart from ischemia-reperfusion injury. We have recently identified a novel and orally active PARP-1 inhibitor, KR-33889 [2-[methoxycarbonyl(4-methoxyphenyl)-methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide], and its major metabolite, KR-34285 [2-[carboxy(4-methoxyphenyl)methylsulfanyl]-1H-benzimidazole-4-carboxylic acid amide]. KR-33889 potently inhibited PARP-1 activity with an IC50 value of 0.52 ± 0.10 μM. In H9c2 myocardial cells, KR-33889 (0.03–30 μM) showed a resistance to hydrogen peroxide (2 mM)-mediated oxidative insult and significantly attenuated activation of intracellular PARP-1. In anesthetized rats subjected to 30 min of coronary occlusion and 3 h of reperfusion, KR-33889 (0.3–3 mg/kg i.v.) dose-dependently reduced myocardial infarct size. KR-34285, a major metabolite of KR-33889, exerted similar patterns to the parent compound with equi- or weaker potency in the same studies described above. In separate experiments for the therapeutic time window study, KR-33889 (3 mg/kg i.v.) given at preischemia, at reperfusion or in both, in rat models also significantly reduced the myocardial infarction compared with their respective vehicle-treated group. Furthermore, the oral administration of KR-33889 (1–10 mg/kg p.o.) at 1 h before occlusion significantly reduced myocardial injury. The ability of KR-33889 to inhibit PARP in the rat model of ischemic heart was confirmed by immunohistochemical detection of poly(ADP-ribose) activation. These results indicate that the novel PARP inhibitor KR-33889 exerts its cardioprotective effect in in vitro and in vivo studies of myocardial ischemia via potent PARP inhibition and also suggest that KR-33889 could be an attractive therapeutic candidate with oral activity for several cardiovascular disorders, including myocardial infarction. The American Society for Pharmacology and Experimental Therapeutics ER -